New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
Clarivate (NYSE:CLVT) and Healthcare Executive have released a report titled 'A Decade of Innovation, A Decade to Come,' analyzing Mainland China's transformation into a global biopharma powerhouse. The report highlights China's advancement to become one of the top three countries for initial drug launches, with its R&D expenditure growing 3.5 times over the past decade. Key developments include regulatory reforms, increased investment, and improved patient access to therapies. The National Reimbursement Drug List negotiations have reduced drug costs by 50-60%, while China's share of global licensing deals has increased from 6.5% to nearly 9% since 2015.
Clarivate (NYSE:CLVT) e Healthcare Executive hanno pubblicato un rapporto intitolato 'Un Decennio di Innovazione, Un Decennio a Venire', che analizza la trasformazione della Cina continentale in una potenza globale nella biopharma. Il rapporto evidenzia i progressi della Cina per diventare uno dei primi tre paesi per il lancio di nuovi farmaci, con una spesa in R&D aumentata di 3,5 volte nell'ultimo decennio. Sviluppi chiave includono riforme normative, un aumento degli investimenti e un miglioramento dell'accesso dei pazienti alle terapie. Le negoziazioni sulla National Reimbursement Drug List hanno ridotto i costi dei farmaci del 50-60%, mentre la quota della Cina negli accordi di licenza globali è aumentata dal 6,5% a quasi 9% dal 2015.
Clarivate (NYSE:CLVT) y Healthcare Executive han publicado un informe titulado 'Una Década de Innovación, Una Década por Venir', que analiza la transformación de China continental en una potencia global de biopharma. El informe destaca el avance de China para convertirse en uno de los tres principales países para lanzamientos de nuevos medicamentos, con su gasto en I+D creciendo 3.5 veces en la última década. Los desarrollos clave incluyen reformas regulatorias, aumento de la inversión y mejor acceso de los pacientes a las terapias. Las negociaciones sobre la Lista Nacional de Medicamentos Reembolsables han reducido los costos de los medicamentos en un 50-60%, mientras que la participación de China en los acuerdos de licencia globales ha aumentado del 6.5% a casi 9% desde 2015.
Clarivate (NYSE:CLVT)와 Healthcare Executive는 '혁신의 10년, 다가오는 10년'이라는 제목의 보고서를 발표하여 중국 본토가 글로벌 생명공학 강국으로 변모한 과정을 분석했습니다. 이 보고서는 중국이 새로운 약물 출시의 상위 세 국가 중 하나로 성장했음을 강조하며, R&D 지출이 지난 10년 동안 3.5배 증가했습니다. 주요 발전으로는 규제 개혁, 투자 증가, 치료에 대한 환자 접근성 향상이 포함됩니다. 국가재정약품목록 협상에 의해 약물 비용이 50-60% 감소되었으며, 2015년 이후 중국의 글로벌 라이센싱 거래 비율이 6.5%에서 거의 9%로 증가했습니다.
Clarivate (NYSE:CLVT) et Healthcare Executive ont publié un rapport intitulé 'Une Décennie d'Innovation, Une Décennie à Venir', analysant la transformation de la Chine continentale en une puissance mondiale de biopharma. Le rapport souligne l'avancement de la Chine pour devenir l'un des trois premiers pays pour les lancements de nouveaux médicaments, avec ses dépenses en R&D ayant augmenté de 3,5 fois au cours de la dernière décennie. Les développements clés incluent des réformes réglementaires, une augmentation des investissements et un meilleur accès des patients aux thérapies. Les négociations sur la Liste Nationale des Médicaments Remboursables ont réduit les coûts des médicaments de 50-60%, tandis que la part de la Chine dans les accords de licence mondiaux est passée de 6,5% à près de 9% depuis 2015.
Clarivate (NYSE:CLVT) und Healthcare Executive haben einen Bericht mit dem Titel 'Ein Jahrzehnt der Innovation, Ein Jahrzehnt, das bevorsteht' veröffentlicht, der die Transformation des Festlandchinas zu einer globalen Biopharma-Macht analysiert. Der Bericht hebt Chinas Fortschritt hervor, eines der drei wichtigsten Länder für die Einführung neuer Medikamente zu werden, wobei die F&E-Ausgaben in den letzten zehn Jahren um 3,5 Mal gestiegen sind. Zu den wichtigsten Entwicklungen gehören regulatorische Reformen, erhöhte Investitionen und verbesserter Patienten Zugang zu Therapien. Die Verhandlungen zur Nationalen Erstattungsliste für Medikamente haben die Arzneimittelkosten um 50-60% gesenkt, während Chinas Anteil an globalen Lizenzverträgen seit 2015 von 6,5% auf fast 9% gestiegen ist.
- China has become one of the top three countries globally for initial drug launches
- R&D expenditure growth outpaces UK and US rates, increasing 3.5x over the past decade
- National Reimbursement Drug List negotiations reduced drug costs by 50-60%
- Share of global licensing and service deals increased from 6.5% to 9% since 2015
- Country leads in research publication and patent filing in life sciences
- None.
Insights
The report highlights China's significant transformation in the global biopharma landscape, with several key metrics indicating substantial market growth. The increase in China's share of global licensing deals from
For Clarivate investors, this represents a strategic positioning in the growing Chinese biopharma market. The company's comprehensive data services and analytics tools are becoming increasingly valuable as China's biopharma sector expands. The partnership with the China Pharmaceutical Enterprises Association strengthens Clarivate's market position and potential revenue streams from this rapidly growing market.
The regulatory and policy reforms in China's biopharma sector present significant opportunities for global stakeholders. The Marketing Authorization Holder system and streamlined approval processes have fundamentally altered the market dynamics. The country's emergence among the top three nations for initial drug launches demonstrates the effectiveness of these reforms.
The systematic price negotiations through NRDL, while reducing costs by
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders
Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval timelines, raised regulatory standards, and improved patient access to advanced therapies. Insights from the Institute for Scientific Information™ show that
Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "Mainland China's ascent in the biopharma sector reflects the power of sustained investment and strategic reform. This report not only highlights the impressive achievements of the past decade but also underlines the far-reaching potential for Chinese biopharma companies to drive global medical innovation and enhance patient outcomes worldwide."
Tan Yong, Vice President of China Pharmaceutical Enterprises Association and Publisher of Healthcare Executive, noted: "The pharmaceutical industry is poised for significant and transformative changes in the upcoming decade, driven by heightened competition. Rapid innovation and intense competition have reshaped market dynamics, leading to more focused and sustainable growth. The report offers the industry a glimpse of how Chinese pharmaceutical companies can prioritize innovation and international expansion in the next decade."
Alice Zeng, Senior Solution Consultant, Life Sciences & Healthcare, Clarivate, added: "This report is an invaluable resource for global industry stakeholders. For pharma companies worldwide, it provides a timely understanding of Mainland China's biopharma landscape, covering the opportunities for international collaboration and the potential for accelerated market entry."
The report highlights Mainland China's regulatory advancements, rapid drug launch growth, and expanding domestic R&D role. Key updates include the National Reimbursement Drug List (NRDL), where systematic price negotiations have cut costs by 50
Key insights in A Decade of Innovation, A Decade to Come, include:
- Impactful policy reforms: How regulatory initiatives such as the Marketing Authorization Holder (MAH) system and priority review programs have streamlined approvals and bolstered R&D.
- Healthcare accessibility and innovation: An examination of Mainland China's healthcare reforms, including the expansion of the NRDL and commercial health insurance, increasing access to cutting-edge therapies.
- Investment and R&D growth: Analysis of Mainland China's record-breaking R&D investment, driving advancements in oncology, anti-infectives, and emerging therapeutic areas.
- Global Integration and market opportunities: Insights into the rise of Mainland China's biopharma sector as a global player, including the increase in multinational collaborations and first-to-market launches.
With Mainland China's share of first-time global drug launches growing, and as new therapeutic areas advance, A Decade of Innovation, A Decade to Come provides timely, in-depth insights for international investors, multinational pharmaceutical companies, and healthcare stakeholders who seek to understand Mainland China's role in shaping the future of the biopharma landscape.
The A Decade of Innovation, A Decade to Come report draws on comprehensive data and tools trusted by the global life sciences community, including Cortellis Competitive Intelligence, Cortellis Regulatory Intelligence™, Disease Landscape & Forecast, Cortellis Deals Intelligence, Cortellis Clinical Trials Intelligence™, Cortellis Product Intelligence™, Real World Data and Analytics, Access and reimbursement payer studies, BioWorld™, Web of Science™ and Derwent Innovation™ among others. Compiled by Clarivate analysts using data gathered prior to August 31, 2024, this report reflects Clarivate's commitment to supporting drug, device, and medical technology lifecycles. By combining patient journey data, therapeutic insights, and AI-driven analytics, Clarivate enables evidence-based decisions that advance human health.
To learn more about the Clarivate report, A Decade of Innovation, A Decade to Come, visit here.
About Healthcare Executive
With media as the outpost, conference as the platform, live video broadcasting as the tool, and expert pharmaceutical industry observers and recorders as the living force, Healthcare Executive (E药经理人) brings the top consensus of entrepreneurs, scientists, and investors in the pharmaceutical industry together on the one hand, and on the other hand gathers multi-dimensional and multi-level resources from the whole industry chain. We are dedicated to providing in-depth professional communication opportunities and influential solutions for the whole industry chain in their whole life cycle. In this regard, we make connections with client requirements upstream and downstream and make preparations for the overseas strategy in their international programs.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com
1 Source: Global Research Report:
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307317.html
SOURCE Clarivate Plc
FAQ
What is the growth rate of China's R&D expenditure according to Clarivate (CLVT)?
How much has the National Reimbursement Drug List reduced drug costs in China as reported by Clarivate (CLVT)?
What is China's current share of global licensing and service deals according to Clarivate (CLVT)?
